The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity.

Abstract

An integrated analysis of safety and reactogenicity data was undertaken for 28 randomized, placebo-controlled, double-blind Phase II and III trials (DBRCTs) of the oral live-attenuated human rotavirus vaccine, Rotarix™ (GlaxoSmithKline Vaccines). Healthy infants aged 6-20 wk received 2 or 3 doses of vaccine (n=56562) or placebo (n=45512) at 4- to 8-wk… (More)
DOI: 10.4161/hv.26476

Topics

Cite this paper

@article{Buyse2014TheHR, title={The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity.}, author={H. Buyse and C. Vinals and Naveen Karkada and Htay Htay Han}, journal={Human vaccines & immunotherapeutics}, year={2014}, volume={10 1}, pages={19-24} }